AU2020288640A1 - Methods of treating and/or preventing psoriasis - Google Patents

Methods of treating and/or preventing psoriasis Download PDF

Info

Publication number
AU2020288640A1
AU2020288640A1 AU2020288640A AU2020288640A AU2020288640A1 AU 2020288640 A1 AU2020288640 A1 AU 2020288640A1 AU 2020288640 A AU2020288640 A AU 2020288640A AU 2020288640 A AU2020288640 A AU 2020288640A AU 2020288640 A1 AU2020288640 A1 AU 2020288640A1
Authority
AU
Australia
Prior art keywords
administered
days
subject
methods disclosed
affected area
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020288640A
Other languages
English (en)
Inventor
Wing Kai CHAN
Min-fun Rudolf Kwan
Johnson Yiu-Nam Lau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atnx Spv LLC United States
Original Assignee
Atnx Spv LLC United States
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atnx Spv LLC United States filed Critical Atnx Spv LLC United States
Publication of AU2020288640A1 publication Critical patent/AU2020288640A1/en
Assigned to ATNX SPV, LLC reassignment ATNX SPV, LLC Request for Assignment Assignors: ATHENEX, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2020288640A 2019-06-05 2020-06-05 Methods of treating and/or preventing psoriasis Abandoned AU2020288640A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962857796P 2019-06-05 2019-06-05
US62/857,796 2019-06-05
PCT/US2020/036238 WO2020247706A1 (en) 2019-06-05 2020-06-05 Methods of treating and/or preventing psoriasis

Publications (1)

Publication Number Publication Date
AU2020288640A1 true AU2020288640A1 (en) 2021-12-23

Family

ID=73653388

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020288640A Abandoned AU2020288640A1 (en) 2019-06-05 2020-06-05 Methods of treating and/or preventing psoriasis

Country Status (8)

Country Link
US (1) US20220305021A1 (https=)
EP (1) EP3980021A4 (https=)
JP (2) JP2022535267A (https=)
AU (1) AU2020288640A1 (https=)
CA (1) CA3142477A1 (https=)
IL (1) IL288524A (https=)
TW (1) TW202112379A (https=)
WO (1) WO2020247706A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939529B2 (en) * 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
US7935697B2 (en) * 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
WO2015054500A2 (en) * 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
CA2969090C (en) * 2014-12-23 2023-05-02 Novartis Ag Triazolopyrimidine compounds and uses thereof
RU2017134379A (ru) * 2015-03-25 2019-04-03 Новартис Аг Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4
CN118384166A (zh) * 2016-08-12 2024-07-26 阿西纳斯公司 用于调节激酶级联的联芳组合物和方法
WO2018165647A1 (en) * 2017-03-10 2018-09-13 Athenex, Inc. Methods of treating and/or preventing actinic keratosis

Also Published As

Publication number Publication date
JP2022535267A (ja) 2022-08-05
TW202112379A (zh) 2021-04-01
EP3980021A1 (en) 2022-04-13
US20220305021A1 (en) 2022-09-29
IL288524A (en) 2022-01-01
CA3142477A1 (en) 2020-12-10
EP3980021A4 (en) 2023-06-14
JP2025032128A (ja) 2025-03-11
WO2020247706A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
Sheu et al. Dapsone therapy for pustular psoriasis: case series and review of the literature
JP2023015269A (ja) 光線角化症を治療および／または予防する方法
EP2968309A2 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
CN112689512B (zh) 用于治疗银屑病的组合物和方法
CN107072959A (zh) 包含二高γ亚麻酸(DGLA)的医药组合物以及其用途
AU2015274532B2 (en) Stabilized oxymetazoline formulations and their uses
WO2014164281A1 (en) Use of levocetirizine and montelukast in the treatment of anaphylaxis
CN1327843C (zh) 氟马西尼在用于可卡因依赖治疗药物制备中的应用
US20200397787A1 (en) Treatment of hand eczema
WO2022253034A1 (zh) 吡咯并嘧啶类化合物的用途
AU2020288640A1 (en) Methods of treating and/or preventing psoriasis
Lewis Therapeutic progress II: treatment of psoriasis
US20240024273A1 (en) Topical administration of 2-(diethylamino)ethyl 2-(4-isobutylphenyl)proprionate for treatment of diseases
WO2017192504A1 (en) Treating activated dermal conditions with agents that target energy metabolism
US6693100B1 (en) Pharmaceutical compositions for treating psoriasis
US20130059813A1 (en) Treatment of dermatological conditions
CN120000644A (zh) 中重度斑块型银屑病的治疗
US20200054664A1 (en) Metabolic supplement formulation and methods of use for treating depression and anxiety
AU2023230563A1 (en) Medication
CN120284871A (zh) 用于鼻腔的含奥洛他定与溴莫尼定的复方制剂组合物及其制备方法
HRP20020201A2 (en) Pharmaceutical compositions for treating psoriasis
Wajid A Comparative Study of the Efficacy and Safety of Topical Calcitriol with Calcitriol and Clobetasol in Chronic Plaque Psoriasis
Tate Chronic psoriasis
Yu et al. Pharmacokinetic profile of oral tazarotene1
HK1236391A1 (en) Stabilized oxymetazoline formulations and their uses

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ATNX SPV, LLC

Free format text: FORMER APPLICANT(S): ATHENEX, INC.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted